Benefit of simultaneous rhG-CSF and methylprednisolone 'pulse' therapy for methotrexate-induced bone marrow failure in rheumatoid arthritis.

Abstract

A 74-year-old female with seropositive rheumatoid arthritis developed severe bone marrow failure after the treatment with very low-dose methotrexate (5 mg/week for 3 weeks). Hematological data showed severe pancytopenia with 0% neutrophils and bone marrow disclosed thoroughly hypocellular marrow. Shortly after the treatment with simultaneous rhG-CSF and methylprednisolone 'pulse' therapy, pancytopenia was ameliorated and bone marrow examination revealed hypercellular marrow with increasing maturation of hematopoietic components. Hematological parameters were maintained within the normal range with a low dose of prednisolone.

• Authors: H Kondo, Y Date
• Journal: International journal of hematology (Int J Hematol) Vol. 65 Issue 2 Pg. 159-63 (Feb 1997) ISSN: 0925-5710 [Print] Japan
• PMID: 9071820 (Publication Type: Case Reports, Journal Article)

Chemical References

• Antirheumatic Agents
• Recombinant Proteins
• Granulocyte Colony-Stimulating Factor
• Methylprednisolone
• Methotrexate

Topics

• Aged
• Antirheumatic Agents (adverse effects, therapeutic use)
• Arthritis, Rheumatoid (drug therapy)
• Bone Marrow Diseases (chemically induced, drug therapy)
• Drug Therapy, Combination
• Female
• Granulocyte Colony-Stimulating Factor (administration & dosage)
• Humans
• Methotrexate (adverse effects, therapeutic use)
• Methylprednisolone (administration & dosage)
• Recombinant Proteins (administration & dosage)